BRIGHTLINE-1: A PHASE II/III, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY OF BRIGIMADLIN (BI 907828) COMPARED TO DOXORUBICIN AS FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA

Registry ID

1403-0008

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Start date

2023-04-05

Completion date

2026-02-03

Last update

2022-02-11

Conditions

• LIPOSARCOMA

Related clinical trials

• A PHASE 2 SINGLE ARM OPEN-LABEL CLINICAL TRIAL OF ADP-A2M4 SPEAR T CELLS IN SUBJECTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA (SPEARHEAD 1 STUDY)
• A PHASE 2-3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)

View on source registry